Executive Team

Appointed in 2019, Keeley leads Waters’ global legal and compliance functions, overseeing the company’s sustainability program, and providing strategic counsel on governance, regulatory, and enterprise risk matters.

Keeley joined Waters in 2006 as Assistant General Counsel and has since held a series of senior leadership roles, including Associate General Counsel, Vice President & Deputy General Counsel, and Assistant Secretary. She serves as a key advisor to the executive leadership team and the Board of Directors, guiding the company on business transactions, commercial strategy, mergers and acquisitions, intellectual property, compliance, corporate governance, litigation, and organizational matters.

Before joining Waters, Keeley practiced law at Goodwin Procter LLP and Testa, Hurwitz & Thibeault, LLP.

She has been recognized by Massachusetts Lawyers Weekly as an In House Icon (2025) and as one of the Top Women of the Law (2017).

Keeley earned her B.A. with honors from the University of California, Davis, and her J.D., magna cum laude, from Boston University School of Law.

Jianqing Bennett was appointed to lead Waters Advanced Diagnostics in 2026. In this role, she leads Waters in vitro diagnostics (IVD) business and the development and execution of the long-term strategy to advance diagnostics through Waters’ technology platforms, including mass spectrometry, clinical microbiology, and molecular diagnostics. Her focus is on enabling faster, more accurate, and earlier diagnosis and therapeutic intervention to improve patient outcomes.

Previously, Jianqing served as Senior Vice President of the TA Instruments Division of Waters Corporation and led the Clinical Mass Spectrometry business. She has played a key role in driving innovation, growth, and operational excellence. Prior to Waters, she was Senior Vice President, High Growth Markets at Beckman Coulter Diagnostics (a Danaher operating company), where she held full P&L responsibility and led a broad portfolio of in vitro diagnostics solutions, driving revenue growth and market share expansion.

Earlier in her career, Jianqing spent 14 years at Carestream Health, including serving as President of the Medical Digital Business, and held multiple roles at GE Healthcare in China and the United States.

Jianqing holds a B.S. in Biomedical Engineering from Fudan University in Shanghai, China, and an MBA from The University of Iowa.

Steve Conly was appointed to lead Waters Biosciences in 2026, after having led the Biosciences business since 2022 as Worldwide President of BD Biosciences. In that role, he oversaw the strategic, operational, and financial performance of the global organization and helped strengthen its innovation culture as well as the customer and employee experience. The Waters Biosciences portfolio supports research discovery, therapy development, and clinical diagnostics addressing diseases such as cancer and HIV.

Before serving as president, Steve held a series of senior leadership positions across BD Biosciences and BD Diagnostic Solutions, including Vice President and General Manager of Research & Clinical Solutions and Vice President and General Manager of the Microbiology business. In these roles, he led global franchises spanning lab automation, microbiology, informatics, flow cytometry, and single cell technologies. He also played a key role in integrating and scaling the Kiestra microbiology automation business following its acquisition by BD.

Steve earned a Bachelor of Arts and Sciences degree from McGill University, where he majored in Biomedical Sciences and Economics. He currently serves on the boards of the Silicon Valley Leadership Group and the Analytical, Life Science & Diagnostics Association.

Kristen Garvey was appointed to lead the Global Communications function at Waters Corporation in 2019 after joining the company in 2018. She is responsible for Waters’ global communications and brand strategy, overseeing public relations, corporate branding, community involvement, and executive and employee communications. She spearheads global initiatives that elevate Waters’ brand reputation and strengthen its connection with key stakeholders worldwide.

Prior to joining Waters, Kristen led internal communications at EMC and Dell Technologies, playing a significant role in the communication strategy for the largest technology merger in IT history. A marketer at heart, Kristen has held a variety of marketing leadership positions throughout her career.

Kristen serves on the Board of The New England Council and has been appointed to the Board of Trustees for Worcester State University.

She earned a B.A. in communications from the University of Massachusetts Amherst.

Allan Jaenicke was appointed to lead Transformation at Waters Corporation in 2026 to drive integration execution, value capture, and transformation of enterprise capabilities. He previously oversaw Strategy & Operational Excellence in Global Operations, and led the enterprise-wide Center for Process Excellence. In this role, Allan played a pivotal part in shaping operational transformation strategies and advancing the company’s vision for the Enterprise of the Future.

Before joining Waters in December 2020, Allan served as Senior Vice President of Enterprise Agile Transformation at Fidelity Investments, where he led large-scale organizational transformation impacting over 18,000 employees. His earlier consulting career includes key engagements at McKinsey & Company, where he advised major global clients on operating model transformations, post-merger integrations, and corporate strategy across multiple industries.

Prior to his corporate transformation work, Allan was a technology entrepreneur and founder of Imagineer Systems Ltd. The company’s technology led to the development of advanced, Academy Award-winning visual effects tools for film and video post-production, as well as a spinout in-video advertising company, Mirriad.

He holds an MBA from the MIT Sloan School of Management and a Bachelor of Engineering in Information Systems Engineering from Imperial College London.

Chris Ross was appointed to lead Global Operations at Waters Corporation in 2022. He is responsible for Waters worldwide manufacturing, supply chain and distribution, facilities, health and safety, procurement and quality. In July of 2025, Chris was also appointed the Integration Planning Lead for the announced acquisition of the Becton Dickinson Diagnostics Solutions and Bioscience businesses.

Prior to joining Waters, Chris spent 14 years at MilliporeSigma, the $9 billion Life Science business of Merck KGaA, Darmstadt, Germany, where he was most recently the Interim Sector Head of Life Science and Head of Integrated Supply Chain Operations. As Interim Sector Head of Life Science, he was responsible for leading the strategic direction of the business, collaborating with the global scientific community to solve the industry’s toughest problems, making research and biotech production simpler, faster, and safer. As Head of Integrated Supply Chain Operations, he was responsible for global manufacturing, supply chain, and global distribution, driving improvements in cost, quality, and delivery of products. He was appointed US Country Speaker for Merck KGaA, Darmstadt, Germany in 2019, driving a one-company approach and representing the company across the United States.

He earned an MBA from the University of Washington in Seattle and a B.S. in electrical engineering from Worcester Polytechnic Institute.

Dr. Daniel Rush was appointed to lead Global Research & Strategy at Waters Corporation in 2021. In this role, he collaborates with the Executive Committee to develop and operationalize worldwide enterprise strategy, shares responsibility for M&A, and leads the Global Research function. He was appointed as the interim leader for Waters Materials Sciences in 2026.

Prior to joining Waters, Dan served as Vice President, Worldwide Commercialization Strategy & Innovation at Bristol Myers Squibb (BMS), where he led its digital customer model transformation and was responsible for implementing a novel innovation system across Commercial, Medical and Market Access. Prior to BMS, he spent eight years at Novartis in a variety of sales, marketing, and strategy leadership roles, including Head of Global Pharma Strategy, U.S. Launch Lead for Afinitor® and U.S. Marketing Director for Zometa®.

Dan began his career as a chemist in Pharmaceutical R&D at Merck, following a post-doc in materials science at the University of California, Irvine and Sandia National Laboratories.

He earned a B.A. in chemistry and history from Bowdoin College and a Ph.D. in physical organic chemistry from Yale University.